You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Novartis defeated in drug patent application case

Indian companies can produce generic leukemia treatment

NEW DELHI — India’s Supreme Court rejected a patent application by Novartis for a major cancer drug Monday, in a landmark ruling that will permit poor patients continued access to many of the world’s best medicines, at least for a while.

The ruling allows Indian makers of generic drugs to continue making copycat versions of the drug Gleevec — also spelled Glivec in Europe and elsewhere — which provides such a miraculous cure for some forms of leukemia that the Food and Drug Administration approved the medicine in the United States in 2001 in record time.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week